

4016

Governance: A

AVALON PHARMA

Middle East Pharmaceutical Industries Co.

59.00 SAR / Share

As of: May 28, 2026

11.3x

P/E RATIO

Trailing 12 Months

2.8x

P/B RATIO

Price to Book Value

5.3%

DIVIDEND YIELD

Annual Dividend / Share

1.18B SAR

MARKET CAP

Total Valuation

0.89

BETA

Systematic Risk Index

21.2%

NET MARGIN

Net Profit / Revenue

Company Profile

Middle East Pharmaceutical Industries Company (the Company) and its subsidiaries (collectively referred to as the Group) are engaged in manufacturing medicines, medicated and non-medicated creams and gels. The Company has ten branches in Saudi Arabia and one branch in Dubai, UAE. The Group generates revenue from private, public, and export customers.

The Story

"Avalon Pharma is a high-return pharmaceutical manufacturer in Saudi Arabia, combining robust double-digit revenue growth with exceptional returns on capital and strategic capacity expansions."

Financial Metric	Value
Return on Capital (ROIC)	21.9%
Debt-to-Equity Ratio	7.0%
Sustainable Growth Rate	+10.8%

Growth Story

Revenue has grown steadily from 338.4 million SAR in FY 2023 to 394.0 million SAR in FY 2024, 460.5 million SAR in FY 2025, and reached 493.3 million SAR on a TTM basis. This growth is supported by a 5-year average reinvestment rate of 49.22% and a high 5-year average ROIC of 21.88%, yielding a sustainable growth rate... [\[Read full story\]](#)

Corporate Governance Profile

Rating: A

We track 11 key governance disclosures in our database.

Profitability Dynamics

This profitability is driven by strong margins, with a TTM operating margin of 23.69% and a net profit margin of 21.19%, translating to a TTM net income of 104.5 million SAR. The company's high-margin private customer segment remains the primary driver of profitability, generating 91.9 million SAR of the 130.1 million... [\[Read full story\]](#)

Risk & Capital Structure Factors

The company manages its financial risk through a mix of short-term Murabaha facilities and long-term development loans, carrying a total debt of 83.1 million SAR against a cash balance of 18.8 million SAR. While the company has secured long-term financing from the Saudi Industrial Development Fund (SIDF) and... [\[Read full story\]](#)